Vancouver, British Columbia, April 30, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery announced the financial results for its...
Data highlights novel PARP1 and ATR inhibitors with progress toward next-generation therapies for hard-to-treat malignancies Vancouver, British Columbia, April 29, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing...
Vancouver, British Columbia, April 29, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce the appointments of...
Vancouver, British Columbia, April 22, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to congratulate...
Be in the know with the Rakovina Therapeutics monthly investor newsletter! Each month you’ll find out what’s going on with the company and be the first to receive news release straight to your inbox.
Recent Comments